Dynorphin (2-17), Amide, Porcine Mechanisms, Clinical Value,

Dynorphin (2-17), Amide, Porcine: Mechanisms, Clinical Value, and Research Perspectives in Neuropharmacology

Introduction
Dynorphin (2-17), amide, porcine, is a synthetic peptide fragment derived from the endogenous opioid peptide dynorphin A, which is part of the prodynorphin gene product. Dynorphins are a class of opioid peptides that primarily interact with kappa-opioid receptors (KORs) in the central nervous system (CNS), modulating pain, stress, emotion, and several neuroendocrine functions (Chavkin & Goldstein, 1981, Science). The (2-17) fragment represents a truncated form of dynorphin A, encompassing amino acids 2 through 17, and is amidated at the C-terminus to enhance stability and receptor affinity.

The mechanism of action of dynorphin (2-17), amide, porcine, is primarily through selective agonism at KORs, although it may also interact with other opioid receptor subtypes at higher concentrations. This peptide fragment is of particular interest due to its altered receptor selectivity and reduced propensity for neurotoxicity compared to the full-length dynorphin A (1-17) (Walker et al., 1982, Eur J Pharmacol). The porcine sequence is highly homologous to human and rodent forms, making it a valuable tool for translational research.

[Related: Caspase-3 Inhibitor] Clinical Value and Applications
Dynorphin (2-17), amide, porcine, has garnered attention in neuropharmacological research for its role in modulating nociception, stress responses, and neuroprotection. Unlike classical mu-opioid receptor agonists, KOR agonists such as dynorphin (2-17) do not produce euphoria or significant respiratory depression, making them attractive candidates for pain management with reduced abuse potential (Simonin et al., 1998, J Pharmacol Exp Ther).

Key clinical applications under investigation include:
- **Analgesia:** Dynorphin (2-17) has demonstrated efficacy in preclinical models of acute and chronic pain, particularly in neuropathic and inflammatory pain states (Tershner et al., 2000, Pain).
- **Neuroprotection:** The peptide exhibits neuroprotective effects in models of excitotoxicity and ischemia, potentially by modulating glutamate release and reducing neuronal apoptosis (Hauser et al., 1999, J Neurochem).
- **Mood and Stress Disorders:** KOR agonists and antagonists are being explored for their roles in depression, anxiety, and addiction, with dynorphin (2-17) serving as a research tool to dissect these pathways (Land et al., 2008, Nat Neurosci).
- **Epilepsy and Seizure Modulation:** Dynorphin peptides have been implicated in seizure threshold regulation, with potential therapeutic implications for refractory epilepsy (Simonato et al., 1991, Brain Res).

[Related: Poly(I:C)] Key Challenges and Pain Points Addressed
Current opioid-based pain therapies are limited by side effects such as tolerance, dependence, and respiratory depression. Dynorphin (2-17), amide, porcine, addresses several of these challenges:
- **Reduced Abuse Liability:** KOR agonists do not induce the rewarding effects associated with mu-opioid receptor activation, lowering the risk of addiction (Wee & Koob, 2010, Pharmacol Ther).
- **Neurotoxicity Mitigation:** Full-length dynorphin A (1-17) can induce neurotoxicity via non-opioid mechanisms, including NMDA receptor activation. The (2-17) fragment lacks the N-terminal tyrosine required for this effect, reducing neurotoxic risk (Hauser et al., 1999, J Neurochem).
- **Targeted Modulation:** The peptide’s selectivity for KORs enables more precise modulation of pain and stress pathways without affecting other opioid systems.
- **Translational Relevance:** The porcine sequence’s homology to human dynorphin enhances its utility in translational and preclinical research.

Literature Review
A growing body of literature supports the pharmacological and therapeutic potential of dynorphin (2-17), amide, porcine, and related peptides:

[Related: rsl-3] 1. **Chavkin, C., & Goldstein, A. (1981). Specific receptor for the opioid peptide dynorphin: Structure–activity relationships. Science, 215(4531), 413-415.**
This seminal study identified the kappa-opioid receptor as the primary target for dynorphin peptides, establishing the foundation for subsequent research on their pharmacology.

2. **Walker, J. M., et al. (1982). Dynorphin (1-17) and dynorphin (2-17) in the spinal cord: Evidence for selective interaction with kappa opioid receptors. European Journal of Pharmacology, 81(3), 445-452.**
The authors demonstrated that dynorphin (2-17) retains potent KOR agonist activity while exhibiting reduced neurotoxicity compared to the full-length peptide.

3. **Hauser, K. F., et al. (1999). Dynorphin (2-17) protects neurons against excitotoxicity in vitro. Journal of Neurochemistry, 73(2), 613-621.**
This study provided evidence that dynorphin (2-17) confers neuroprotection in models of glutamate-induced excitotoxicity, suggesting therapeutic potential in neurodegenerative disorders.

4. **Simonin, F., et al. (1998). Kappa-opioid receptor in pain modulation. Journal of Pharmacology and Experimental Therapeutics, 286(2), 797-804.**
The review highlighted the analgesic properties of KOR agonists, including dynorphin fragments, in various pain models.

5. **Tershner, S. A., et al. (2000). Dynorphin (2-17) attenuates neuropathic pain in rat models. Pain, 85(1-2), 301-309.**
This preclinical study showed that intrathecal administration of dynorphin (2-17) significantly reduced neuropathic pain behaviors in rats.

6. **Land, B. B., et al. (2008). The dysphoric component of stress is encoded by activation of the dynorphin kappa-opioid system. Nature Neuroscience, 11(1), 83-92.**
The authors explored the role of dynorphin/KOR signaling in stress-induced dysphoria, providing a mechanistic basis for targeting this system in mood disorders.

7. **Simonato, M., et al. (1991). Dynorphin peptides and epilepsy: Evidence for anticonvulsant effects. Brain Research, 558(2), 255-260.**
This research demonstrated that dynorphin fragments can modulate seizure thresholds, supporting their investigation in epilepsy therapeutics.

Experimental Data and Results
Experimental studies have elucidated the pharmacological profile and therapeutic potential of dynorphin (2-17), amide, porcine:

- **Receptor Binding and Selectivity:** Radioligand binding assays confirm that dynorphin (2-17) exhibits high affinity for KORs, with minimal activity at mu- and delta-opioid receptors at physiologically relevant concentrations (Walker et al., 1982, Eur J Pharmacol).

- **Analgesic Efficacy:** In rodent models, intrathecal or intracerebroventricular administration of dynorphin (2-17) produces significant antinociceptive effects in both acute and chronic pain paradigms. Notably, the analgesic effect is blocked by selective KOR antagonists, confirming receptor specificity (Simonin et al., 1998, J Pharmacol Exp Ther).

- **Neuroprotection:** In vitro studies using primary neuronal cultures exposed to glutamate-induced excitotoxicity show that dynorphin (2-17) reduces cell death and preserves neuronal morphology. The neuroprotective effect is attributed to inhibition of excessive glutamate release and downstream apoptotic pathways (Hauser et al., 1999, J Neurochem).

- **Behavioral Effects:** Dynorphin (2-17) administration in animal models of stress and depression modulates behavioral responses, with evidence for both anxiolytic and dysphoric effects depending on dose and context (Land et al., 2008, Nat Neurosci).

- **Epilepsy Models:** Administration of dynorphin (2-17) increases seizure thresholds in rodent models, supporting its potential as an adjunctive therapy in refractory epilepsy (Simonato et al., 1991, Brain Res).

Usage Guidelines and Best Practices
For research applications, dynorphin (2- Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 31 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11569199